IDH2 mutation

News alerts, weekly reports and conference planners

Entrez ID:

3418

Related biomarkers:

Expression

Mutation

Others

‹

IDH2 overexpression (0)

›

Related tests:

Oncomine™ Dx Target Test (10)

IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1	enasidenib Sensitive: A1 - Approval enasidenib Sensitive : A1
IDH2 mutation	Oligodendroglioma	IDH2 mutation	Oligodendroglioma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	cytarabine Resistant: B - Late Trials cytarabine Resistant : B	cytarabine Resistant: B - Late Trials cytarabine Resistant : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	temozolomide gel Sensitive: B - Late Trials temozolomide gel Sensitive : B	temozolomide gel Sensitive: B - Late Trials temozolomide gel Sensitive : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	Sensitive: B - Late Trials Sensitive : B	Sensitive: B - Late Trials Sensitive : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	vorasidenib Sensitive: B - Late Trials vorasidenib Sensitive : B	vorasidenib Sensitive: B - Late Trials vorasidenib Sensitive : B
IDH2 mutation	Acute Lymphocytic Leukemia	IDH2 mutation	Acute Lymphocytic Leukemia	enasidenib Sensitive: B - Late Trials enasidenib Sensitive : B	enasidenib Sensitive: B - Late Trials enasidenib Sensitive : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	TG02 Sensitive: C2 – Inclusion Criteria TG02 Sensitive : C2	TG02 Sensitive: C2 – Inclusion Criteria TG02 Sensitive : C2
IDH2 mutation	Glioma	IDH2 mutation	Glioma	pamiparib Sensitive: C2 – Inclusion Criteria pamiparib Sensitive : C2	pamiparib Sensitive: C2 – Inclusion Criteria pamiparib Sensitive : C2
IDH2 mutation	Cholangiocarcinoma	IDH2 mutation	Cholangiocarcinoma	dasatinib Sensitive: C2 – Inclusion Criteria dasatinib Sensitive : C2	dasatinib Sensitive: C2 – Inclusion Criteria dasatinib Sensitive : C2
IDH2 mutation	Myelodysplastic Syndrome	IDH2 mutation	Myelodysplastic Syndrome	enasidenib Sensitive: C2 – Inclusion Criteria enasidenib Sensitive : C2	enasidenib Sensitive: C2 – Inclusion Criteria enasidenib Sensitive : C2
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	MEN1703 Sensitive: C2 – Inclusion Criteria MEN1703 Sensitive : C2	MEN1703 Sensitive: C2 – Inclusion Criteria MEN1703 Sensitive : C2
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials cytarabine / daunorubicin liposomal formulation Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3	venetoclax + enasidenib Sensitive: C3 – Early Trials venetoclax + enasidenib Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3	venetoclax + RG7388 Sensitive: C3 – Early Trials venetoclax + RG7388 Sensitive : C3
IDH2 mutation	Peripheral T-cell Lymphoma	IDH2 mutation	Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
IDH2 mutation	Chronic Myelomonocytic Leukemia	IDH2 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3	venetoclax + ABBV-621 Sensitive: C3 – Early Trials venetoclax + ABBV-621 Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3

IDH2 mutation

Associations